TITLE

Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection: A Pilot Study in São Paulo, Brazil

AUTHOR(S)
Casseb, Jorge; Da Silva Duarte, Alberto Jos
PUB. DATE
July 2005
SOURCE
AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1–infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes mellitus, osteopenia and hyperlipidemia. Recently, new strategies such as short-cycle structured intermittent therapy (SIT; 7 days without therapy followed by 7 days with HAART) have been suggested. We tested this strategy in seven (four women and three men; mean of age 39 of years) HIV-positive individuals, all of whom had CD4+ T cell counts greater than 500 cells/mm3 and undetectable plasma viral load for at least 2 years. Our results indicated no opportunistic diseases or CD4 cell count decrease over a mean follow-up of 26 months. No plasma viral replication was detected in five of seven cases. There was a decrease in triglyceride levels to normal range (not statistically significant), but no modification of cholesterol levels. Thus, we recommend a larger clinical trial to determine if SIT is cost effective in developing countries.
ACCESSION #
17783252

 

Related Articles

  • Low Frequency of Renal Function Impairment During One-Year of Therapy with Tenofovir-Containing Regimens in the Real-World: A Case-Control Study. Padilla, Sergio; Gutiérrez, Félix; Masi, Mar; Cánovas, Víctor; Orozco, Carmen // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p421 

    Concern exists about the risk of nephrotoxicity using tenofovir (TDF) in HIV-infected patients. We performed a retrospective case-control study including 122 consecutive TDF-naive patients who started treatment with TDF-containing regimens and 194 patients receiving antiretroviral therapy with...

  • Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. Young, Jim; Bucher, Heiner C.; Battegay, Manuel; De Geest, Sabina; Spirig, Rebecca; Flepp, Markus; Rickenbach, Martin; Furrer, Hansjakob; Bernasconi, Enos; Hirschel, Bernard; Telenti, Amalio; Vernazza, Pietro // BMJ: British Medical Journal (International Edition);1/3/2004, Vol. 328 Issue 7430, p15 

    Presents a paper on stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy.

  • Retrospective Analysis of Suspending HAART in Selected Patients with Controlled HIV Replication. Jacobs, Benjamin; Neil, Nancy; Aboulafia, David M. // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p429 

    We sought to determine the consequences of stopping highly active antiretroviral therapy (HAART) in a group of 41 HIV-infected individuals with undetectable HIV viral loads and CD4+ counts greater than 500 cells per microliter for 6 months or more. Clinical and laboratory parameters were...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Prevalence and Clinical Implications of Interactive Toxicity Beliefs Regarding Mixing Alcohol and Antiretroviral Therapies among People Living with HIV/AIDS. Kalichman, Seth C.; Amaral, Christina M.; White, Denise; Swetsze, Connie; Pope, Howard; Kalichman, Moira O.; Cherry, Chauncey; Eaton, Lisa // AIDS Patient Care & STDs;Jun2009, Vol. 23 Issue 6, p449 

    Alcohol use is a barrier to medication adherence. Beyond the cognitive effects of intoxication, people living with HIV/AIDS who believe that alcohol should not be mixed with their medications may temporarily stop taking medications when drinking. To examine the effects of alcohol-treatment...

  • Vicriviroc.  // Reactions Weekly;8/11/2007, Issue 1164, p26 

    The article describes the case of a 52-year-old man with HIV infection who developed rhinocerebral zygomycosis during treatment with vicriviroc. It references a study by S. Merchant and colleagues published in the July 31, 2007 issue of the journal "AIDS." The patient started receiving...

  • Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings. Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; Charoenyingwattana, Angkana; Mahasirimongkol, Surakameth; Sura, Thanyachai; Chantratita, Wasun // Current HIV Research;Jan2008, Vol. 6 Issue 1, p65 

    Nevirapine (NVP) is commonly used as a component of first-line antiretroviral therapy in resource-limited countries. We aimed to determine the risk factors for NVP-associated rash among HIV-infected patients who were initiated NVP at low CD4 cell counts in a resource-limited setting. A...

  • HAVE A HARRT.  // Gay Community News;Jun2007, Issue 210, p24 

    The article discusses the highly active anti-retroviral therapy (HAART) drugs and focuses on the reasons why people with HIV are floundering with such drugs. The HAART has revolutionized the treatment of HIV and its development have refined the revolution and mainly focused on minimising side...

  • Has HAART failed? Soresen, Suellyn J.; Busti, Anthony J. // Drug Topics;5/16/2005, Vol. 149 Issue 10, DRUG TOPIC FOR THE... p8 

    Offers advice concerning the condition of an HIV-positive patient who is experiencing virologic failure due to antiretroviral drug interactions. Types of antiretroviral agents being administered to the patient; Increase in drug concentration and toxicity risk; Need for a potent and effective...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics